April is National Testicular Cancer Awareness Month, and at SCRI Oncology Partners, we recognize it is a crucial time to spotlight the importance of awareness and research in the fight against this disease.
Testicular cancer predominantly impacts young and middle-aged men, with the average age of diagnosis being 33. This year, it is projected that 9,720 cases will be identified across the United States.
Dr. Benjamin Garmezy, our renowned GU medical oncologist and the assistant director of Genitourinary Research for Sarah Cannon Research Institute, shared his thoughts on a recent Let Me Help segment with WTVF. He emphasizes the highly curable nature of testicular cancer, with a remarkable cure rate of over 90% for those diagnosed.
Despite the promising prognosis, it is extremely important to remain vigilant and proactive in monitoring any signs and symptoms. In the segment, Dr. Garmezy advocates for monthly self-examinations to help identify any changes in bumps or shape, a critical step in early detection.
In instances where initial treatments for testicular cancer are not successful, SCRI Oncology Partners offers cutting-edge clinical trials. Our commitment to innovation extends to exploring novel therapies such as antibody drug conjugates, T-Cell Engagers and our pioneering CAR-T program. For more information, contact us today.